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| INTRODUC TI ON
Fecal microbiota transplantation (FMT) is a highly effective treatment for recurrent Clostridium difficile infection (RCDI), but its pharmacologic effects are poorly understood. [1] [2] [3] Solid organ transplant (SOT) recipients are typically prescribed a cocktail of immunomodulatory medications to prevent allograft rejection. Many of these medications have a narrow therapeutic index, with potential toxicity at excessive drug levels and increased risk of allograft rejection at sub-therapeutic drug levels. Important drug-drug and drug-food interactions that can affect immunomodulatory drug levels have been described, which aid in anticipating dose changes to remain in the therapeutic range. 4 In a recent prospective microbiome analysis of patients undergoing renal transplantation, Lee et al 5 
noted that
Faecalibacterium prausnitzii fecal microbiota sequence reads were seen in greater abundance among patients who required increases in tacrolimus dosing compared to patients who did not require dose increases. This suggested an association between F. prausnitzii and increased tacrolimus dose requirements. FMT is increasingly being performed for RCDI in immunocompromised patients without report of any adverse effects that have been directly attributed to the fecal material. However, outcomes should be carefully studied in the event FMT should be considered an indication for closer tacrolimus monitoring or dose adjustment.
6-8
We conducted a retrospective review of 10 SOT patients who were prescribed tacrolimus for immunosuppression who underwent FMT for RCDI at our center to evaluate if they required changes in tacrolimus dosing in the 3 months following FMT. Based on the prior report that gut microbiota influence tacrolimus dose requirements, we aimed to evaluate if there was a difference in tacrolimus concentration/daily dose ratio (C/D ratio) 3 months after FMT.
| MATERIAL S AND ME THODS

| Study center and design
This was a single-center retrospective review of all SOT recipients who underwent FMT at Emory University from July 1, 2012
to December 31, 2016. Emory University Hospital is a tertiary care center located in Atlanta, Georgia, and is licensed for 605 beds.
Since 2012, 257 patients have undergone FMT for RCDI at Emory University Hospital and the Emory Clinic and been registered in a secure dataset. All patients included in this dataset with history of SOT were identified by chart review. Patient demographics and key study characteristics were manually extracted by chart review and entered into a secure Excel spreadsheet (Microsoft, Redmond, WA, USA).
Data extraction was confirmed by validation sample of (5/10, 50%) reviewed charts of SOT patients undergoing FMT. Observations were censored at date of last tacrolimus laboratory value, last clinic visit, or death. IRB approval was obtained (study IRB #71277) for this study.
| Fecal donor characteristics
All fecal donors were screened with an initial questionnaire followed by blood and stool testing to exclude potential pathogens as previously described. 7 During the study period, only one patient received fecal material from a known relative, the remaining 9 patients studied received fecal material from anonymous, screened universal fecal donors.
| Data extraction and definitions
Recurrent Clostridium difficile infection was a clinical diagnosis made by treating physicians and a requirement for referral for FMT and subsequent inclusion in this institutional dataset. RCDI is commonly defined as 3 or more episodes of mild to moderate CDI or 2 episodes resulting in hospitalization. 9 All included patients in this study had 2 or more periods of frequent, watery diarrhea with positive laboratory testing for C. difficile on a PCR platform. Transplant patients at 
| Statistical methods
Difference in C/D ratio was tested for statistical significance by 
| RE SULTS
Among 257 patients undergoing FMT from 2012 to 2016, 17 unique patients were identified by chart review who had received a SOT.
Seven of the 17 patients who had received a SOT were excluded from this study. Of these 7 excluded patients, 5 were excluded because they were not prescribed tacrolimus as part of their immunosuppressive regimen at the time of FMT and 2 were excluded because they underwent FMT prior to the time of SOT. Ten patients were ultimately included in this analysis. Demographic data and key patient characteristics of the study population are presented in Table 1 . The median number of days since last SOT was 492, (IQR 298-1181). One patient was missing data for tacrolimus level at 3 months after date of first FMT and was excluded from the Wilcoxon signed-rank test of difference in C/D ratio and total daily dose but included in the plot for illustration of trend. Potential pharmacologic confounders were extracted from the medical record and presented in Table 2 .
Symptoms after first FMT were documented in clinical notes for 9/10 patients. Of these patients, 4 (44%) had no documented adverse effects. Of the patients who experienced adverse effects, these were minor and presented in Table 3 . Two patients underwent allograft biopsy in the year following FMT for allograft dysfunction but these showed no histopathologic evidence of allograft rejection.
Of included patients, 4/10 underwent a second FMT procedure 
| D ISCUSS I ON
These data from 10 SOT patients prescribed tacrolimus as part of an immunosuppressive regimen at the time of undergoing FMT for RCDI did not show a significant difference in tacrolimus total daily dose or C/D ratio at 3 months after FMT compared to 3 months prior to FMT.
In our retrospective study, stool samples were not available for microbiome analyses, thus we were unable to ascertain impact of specific bacteria, such F. prausnitzii, on tacrolimus levels. However, these data report important clinical outcomes of 10 SOT patients undergoing FMT for RCDI. Four of these described 10 patients intestinal graft vs host disease after FMT. 6, 13, 14 In a pilot study of changes in microbiota after renal allograft transplantation, significant differences were noted in diversity in patients who had acute rejection compared to those who did not (Lactobacillales were higher in acute rejection cohort and Clostridiales and Bacteriodales were lower). 15 On the other hand, in a pilot study profiling microbiome changes of 23 renal transplant patients, there was no clustering by PCoA by sampling time point, serum creatinine or rejection events and overall comparisons were not similar between patients. 16 The authors of the report from this pilot study noted that sampling time points did not correlate well with rejection events so it was challenging to estimate the association of changes in microbiota reads and acute rejection. 
| Future directions
Multiple clinical trials are underway investigating the therapeutic potential of FMT for indications beyond RCDI. As FMT utilization increases, further study of its pharmacologic effects on immunomodulatory therapies and its impact on alloimmunity will be important to limit deviations from the narrow therapeutic range of these medications and limit potential risk of allograft rejection. 
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